<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03430037</url>
  </required_header>
  <id_info>
    <org_study_id>17-000472</org_study_id>
    <nct_id>NCT03430037</nct_id>
  </id_info>
  <brief_title>Alleviation by Fisetin of Frailty, Inflammation, and Related Measures in Older Women</brief_title>
  <acronym>AFFIRM</acronym>
  <official_title>AFFIRM: A Phase 2 Randomized, Placebo-Controlled Study of Alleviation by Fisetin of Frailty, Inflammation, and Related Measures in Older Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a pilot study to evaluate whether targeting inflammation will help reduce markers of
      insulin resistance inflammation, bone resorption and physical dysfunction in elderly women
      with gait disturbance. Positive results of this study would lead to the development of a
      larger clinical trial examining the effects of this intervention on age-related dysfunction.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To the researchers' knowledge, there are no published studies utilizing Fisetin in alteration
      of frailty markers. Several studies involve use of Fisetin for its anti-oxidative and
      anti-apoptotic effects in animal models. Fisetin may reduce oxidative stress, alleviate
      hyperglycemia, and improve kidney function. No one has evaluated the biologic markers of
      inflammation and frailty in older postmenopausal women. The researchers plan to evaluate
      markers of frailty and markers of inflammation, insulin resistance, and bone resorption while
      maintaining bone formation in older postmenopausal women.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 6, 2018</start_date>
  <completion_date type="Anticipated">June 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Improved 6 minute walk</measure>
    <time_frame>One Month</time_frame>
    <description>Improved gait speed</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Frail Elderly Syndrome</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fisetin 20/mg/kg/day, orally for 2 consecutive days, for 2 consecutive months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo capsules orally for 2 consecutive days, for 2 consecutive months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Fisetin</intervention_name>
    <description>Flavonoid Family</description>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo oral capsule</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          -  Healthy postmenopausal women

          -  Age â‰¥ 70 years

        Exclusion Criteria

          -  Abnormality in any of the screening laboratory studies (see below)

          -  Presence of significant liver or renal disease

          -  Malignancy (including myeloma)

          -  Malabsorption

          -  Diabetes

          -  Hypoparathyroidism

          -  Hyperparathyroidism

          -  Acromegaly

          -  Cushing's syndrome

          -  Hypopituitarism

          -  Myopathies (increased or low calcium, vitamin D deficiency, elevated creatine kinase
             or ESR)

          -  Undergoing treatment with medications that affect insulin sensitivity, including the
             following:

               -  Metformin (within the previous week),

               -  Glucocorticoids (within the previous month),

               -  Acarbose (within the previous week)

          -  Undergoing treatment with any medications that affect bone turnover, including the
             following:

               -  adrenocorticosteroids (&gt; 3 months at any time or &gt; 10 days within the previous
                  yr), anticonvulsant therapy (within the previous year),

               -  pharmacological doses of thyroid hormone (causing decline of thyroid stimulating
                  hormone below normal),

               -  calcium supplementation of &gt; 1200 mg/d (within the preceding 3 months),

               -  bisphosphonates (within the past 3 yrs),

               -  denosumab,

               -  estrogen (E) therapy or treatment with a selective E receptor modulator, or
                  teriparatide (within the past yr).

          -  Subjects with a fracture within the past year

          -  Subjects taking potentially anti-inflammatory drugs within the last year, such as
             Fisetin

          -  Subjects currently taking drugs that induce inflammation: alkylating agents,
             anthracyclines, platins, other chemotherapy

          -  QTc &gt;450 msec

          -  Tobacco use (smoking or chewing)

          -  Inability to provide informed consent

          -  Total bilirubin &gt; twice the upper limit of normal

          -  Inability to tolerate oral medication

          -  eGFR &lt; 15 ml/ min/ 1.73 m2

          -  Subjects on therapeutic doses of anticoagulants (e.g., warfarin, heparin, low
             molecular weight heparin, factor Xa inhibitors, etc.)

          -  Subjects taking the following antimicrobial agents: Aminoglycosides, Azole antifungals
             (fluconazole, miconazole, voriconazole, itraconazole), Macrolides (clarithromycin,
             erythromycin), Antivirals (nelfinavir, indinavir, saquinavir, ritonavir,
             elbasvir/grazoprevir), Rifampin

          -  Subjects taking proton pump inhibitors who are unable or unwilling to reduce or hold
             therapy prior to and during the 2-day Fisetin dosing

          -  Subjects taking the following other drugs if they cannot be held for at least 2 days
             before and during administration of Fisetin: digoxin, lithium, all statins,
             repaglidine, bosentan, gemfibrozil, olmesartan, enalapril, valsartan, methotrexate,
             corticosteroids, thyroid hormones, eluxadoline, eltrombopag, nitroglycerin,
             pioglitazone, glyburide, enzalutamide, ezetimibe, colchicine, imatinib, cyclosporine,
             tacrolimus, sirolimus, carbamazepine, flecainide, phenytoin, phenobarbital,
             rifampicin, theophylline, warfarin, heparin, full dose acetylsalicylic acid (ASA),
             clopidogrel, celecoxib, desipramine, thioridazine, venlafaxine, tizanidine,
             atomoxetine, voriconazole, citalopram, diazepam, escitalopram, propranolol, clozapine,
             cyclobenzaprine, mexiletine, olanzapine, ondansetron, riluzole

        In order to ensure vitamin D sufficiency, we will also exclude subjects with serum
        25-hydroxyvitamin D levels of &lt; 20 ng/ml.

        Behavioral Modification - Participants will be educated about the risk of excessive
        caffeine usage. Participants will be encouraged to reduce use by 50% prior to and during
        the 2-day drug dosing periods. Due to drug-drug interaction, subjects may not clear the
        caffeine from their system properly/as usual.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>70 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James L Kirkland, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sundeep Khosla, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tammie L Volkman, RN</last_name>
    <phone>507-266-1944</phone>
    <email>volkman.tammie@mayo.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tamara K Evans</last_name>
    <phone>507-266-1944</phone>
    <email>evans.tamara@mayo.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Mayo Clinic in Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tammie L Volkman, RN</last_name>
      <phone>507-266-1944</phone>
      <email>volkman.tammie@mayo.edu</email>
    </contact>
    <contact_backup>
      <last_name>Tamara K Evans</last_name>
      <phone>507-266-1944</phone>
      <email>evans.tamara@mayo.edu</email>
    </contact_backup>
    <investigator>
      <last_name>James Kirkland, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sundeep Khosla, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 5, 2018</study_first_submitted>
  <study_first_submitted_qc>February 9, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 12, 2018</study_first_posted>
  <last_update_submitted>February 9, 2018</last_update_submitted>
  <last_update_submitted_qc>February 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 12, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>James L. Kirkland</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Inflammation</keyword>
  <keyword>Frailty</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

